Tamar Perri

Tamar Perri is a gynecologic oncologist who has published studies on prognostic factors and molecular biomarkers in vulvar squamous cell carcinoma, including PD-L1 expression and p16 status as predictors of outcomes and immunotherapy response. Her institutional experience with recurrent vulvar cancer treated with pembrolizumab and other checkpoint inhibitors has contributed to the small but growing evidence base for immunotherapy in this rare disease. She also analyzes patterns of recurrence and salvage therapy outcomes in refractory vulvar cancer.